Novo Nordisk week recap: CagriSema data, Wegovamy trademark and Awiqli approval
Women on CagriSema hit 20% weight loss far more often than on semaglutide alone, 68.7% vs 38.0%, though Novo calls the comparisons exploratory.
Recap by typeshit. Post by Investseekers on X.